RxDoctor Payments Data

Michelle Korah-Sedgwick, MD

Allergy & Immunology · New Orleans, LANPI 1538483359

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.7% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 25.0% of the total. That places this record below the midpoint for allergy & immunology clinicians in LA, where the typical reported total is $3,029.

$2,065in general payments, 2019–2025

Across 52 payments — averaging $39.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$517
  • Insmed, Inc.$353
  • Takeda Pharmaceuticals U.S.A., Inc.$234
  • Grifols Shared Services North America, Inc.$187
  • Sanofi$162
  • Galderma Laboratories, L.p.$131
  • plus $481 from 11 others
$25,534in research payments, 2019–2025

Across 4 payments — averaging $6383.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$26K

What the payments were for

  • Food & beverage$1,95695%
  • Education$1095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,065 in reported general payments places this provider in the 45th percentile of 62 allergy & immunology providers in Louisiana.

See all allergy & immunology providers in Louisiana

Medicare billing

Part B allowed, 2024
$4,185
Medicare patients
28
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab25$127,702
Dupixent SyringeDupilumab12$45,410
Azelastine Hcl52$1,180
Albuterol Sulfate HfaAlbuterol Sulfate45$1,155
Fluticasone Propionate22$380

Paid to pharmacies, not to this prescriber.

Other allergy & immunology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →